<p>Most common adverse reactions (incidence &ge;20%) in patients were:</p>

<ul>
	<li><strong>As a single agent</strong>: fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, constipation, decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, and vomiting.</li>
	<li><strong>In combination with ipilimumab</strong>: fatigue, diarrhea, rash, pruritus, nausea, musculoskeletal pain, pyrexia, cough, decreased appetite, vomiting, abdominal pain, dyspnea, upper respiratory tract infection, arthralgia, headache, hypothyroidism, decreased weight, and dizziness.</li>
	<li><strong>In combination with ipilimumab and platinum-doublet chemotherapy</strong>: fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus.</li>
	<li><strong>In combination with cabozantinib</strong>: diarrhea, fatigue, hepatotoxicity, palmar-plantar<br />
	erythrodysaesthesia syndrome, stomatitis, rash, hypertension, hypothyroidism,<br />
	musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough,<br />
	and upper respiratory tract infection.</li>
	<li><strong>In combination with fluoropyrimidine- and platinum-containing chemotherapy</strong>: peripheral neuropathy, nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation, and musculoskeletal pain.</li>
</ul>